Apogee Therapeutics Shares Soar on Positive Phase 2 Trial Results

Apogee Therapeutics shares are trading higher after the company announced positive 16-week data from the Phase 2 APEX clinical trial of APG777, demonstrating high efficacy in treating moderate-to-severe atopic dermatitis.